{"commentary":{"count":10,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":6,"podcast":2,"x_thread":2},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06919965\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"MoonRISe-3","nct_id":"NCT06919965","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=moonrise-3-nct06919965. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":"MoonRISe-3","arms":[{"description":"Participants in Group A will have TAR-210 inserted in the bladder on Day 1. TAR-210 will be inserted over a treatment duration of approximately 2 years.","label":"Group A: TAR-210","type":"EXPERIMENTAL"},{"description":"Participants in Group B will receive intravesical mitomycin C (MMC) or gemcitabine (investigator's choice) once weekly for 4 to 6 induction doses followed by maintenance dosing once monthly for up to 1 year. An optional second year of additional maintenance can be added at the investigator's discretion.","label":"Group B: Mitomycin C (MMC) or Gemcitabine","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2032-03-16","type":"ESTIMATED"},"conditions":["Non-Muscle Invasive Bladder Neoplasms"],"enrollment":{"count":220,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"TAR-210","type":"DRUG"},{"name":"Mitomycin C","type":"DRUG"},{"name":"Gemcitabine","type":"DRUG"}],"last_update":"2026-09-28","lead_sponsor":"Janssen Research & Development, LLC","official_title":"A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Investigator's Choice of Intravesical Chemotherapy in Participants With High-risk Non-muscle-invasive Bladder Cancer With Susceptible FGFR Alterations Who Had Received Intravesical Bacillus Calmette-Guérin (BCG)","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2028-04-06","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Disease-free Survival (DFS)","timeFrame":"Up to 5 years"}],"references":[],"start_date":{"date":"2025-09-10","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer","url":"https://clinicaltrials.gov/study/NCT06919965"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/moonrise-3-nct06919965"}